Clinical Trial

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Study acronym: NEXICART-2
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-10-19; most recent amendment 2026-07-12.
Status change: Recruiting → Active, Not Recruiting 2026-07-12
Status change: Not Yet Recruiting → Recruiting 2024-07-15
Trial Details
NCT Number NCT06097832
Lead Sponsor Nexcella Inc.
Collaborators: Immix Biopharma, Inc.
Conditions Light Chain (AL) Amyloidosis
Enrollment 45 participants
Start Date 2024-06-05
Primary Completion 2026-12 (estimated)
Study Completion 2039-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-14